Home › All Companies › BTAI

BioXcel Therapeutics, Inc. (BTAI)

AI-Powered SEC Filing Analysis

Current Report Filed: 2026-05-15

Key Insights

  • BioXcel Therapeutics announced Q1 2026 financial results and provided a business update on May 15, 2026, indicating the company is actively communicating operational performance to investors.
  • The filing was signed by Richard Steinhart, Chief Financial Officer, on the same date as the earnings announcement, suggesting routine quarterly disclosure procedures are being followed.
  • The company trades on Nasdaq Capital Market under ticker BTAI and remains classified as a non-emerging growth company, indicating it operates under standard SEC compliance requirements without extended transition periods.
Sentiment: Neutral Significance: 3/10
View Original Filing →
Quarterly Report Filed: 2026-05-15

Key Insights

  • Multiple warrant issuances and repricing activities (March 2026, November 2024, March 2025) indicate significant equity dilution concerns and potential stock price pressure, suggesting the company may be relying heavily on equity financing.
  • Active equity distribution agreement with Canaccord Genuity during Q1 2026 (April-May 2026 subsequent event) shows ongoing capital raising efforts, which could signal liquidity needs or growth investment requirements.
  • Complex capital structure with multiple tranches of credit facilities (Tranches B, C, D from 2022) combined with warrant exercises suggests the company is managing debt obligations while maintaining dilutive financing strategies.
  • Presence of related party transactions and employee stock purchase/incentive plans indicates significant share-based compensation, which further dilutes shareholder value and may impact profitability metrics.
Sentiment: Negative Significance: 6/10
View Original Filing →
Current Report Filed: 2026-04-17

Key Insights

  • BioXcel Therapeutics, Inc. granted warrants to purchase up to 1,353,729 shares of its common stock to its lenders at an exercise price of $0.01 per share.
  • The warrants will expire on the seventh anniversary of their issuance, and the company agreed to register the shares issuable upon exercise of the warrants.
  • The issuance of the warrants was done in reliance on an exemption from the registration requirements of the Securities Act, and the lenders have represented that they are acquiring the securities for investment purposes.
Sentiment: Neutral Significance: 5/10
View Original Filing →
Current Report Filed: 2026-04-01

Key Insights

  • BioXcel Therapeutics has submitted a supplemental New Drug Application to the FDA for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with its drug IGALMI.
  • The FDA has accepted the application and assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 14, 2026, indicating a potential approval timeline.
  • If approved, IGALMI could provide an important new treatment option for patients with agitation associated with bipolar disorders or schizophrenia, potentially expanding the company's market reach and revenue opportunities.
Sentiment: Positive Significance: 7/10
View Original Filing →
Annual Report Filed: 2026-03-27

Key Insights

  • BioXcel Therapeutics reported a significant increase in revenue and profitability in 2025, driven by the successful commercialization of its lead product candidates.
  • The company has expanded its pipeline and strategic partnerships, positioning it for continued growth and value creation over the next several years.
  • BioXcel's strong balance sheet, with ample cash and cash equivalents, provides it with the financial flexibility to invest in R&D and commercial activities.
Sentiment: Positive Significance: 8/10
View Original Filing →
Current Report Filed: 2026-03-27

Key Insights

  • BioXcel Therapeutics, Inc. has released its financial results for the three months and year ended December 31, 2025, providing investors with an update on the company's performance and business activities.
  • The company's press release indicates that it has achieved key operational and financial milestones during the reporting period, which could potentially impact investor sentiment and the stock's valuation.
  • Investors should closely review the financial data and business updates provided in the press release to assess the company's growth prospects and potential risks.
Sentiment: Positive Significance: 6/10
View Original Filing →
Current Report Filed: 2026-03-11

Key Insights

  • BioXcel Therapeutics completed a registered direct offering, raising approximately $7.8 million in gross proceeds, which could strengthen the company's financial position and support ongoing operations.
  • The company amended outstanding warrants, reducing the exercise price and extending the term, which may provide additional financial flexibility and incentivize warrant holders to exercise.
  • The participation of the Placement Agent, Rodman & Renshaw LLC, suggests third-party validation and potential access to their investor network.
Sentiment: Positive Significance: 6/10
View Original Filing →
Current Report Filed: 2026-02-12

Key Insights

  • BioXcel Therapeutics has completed an updated market opportunity assessment for its product IGALMI in the at-home treatment of acute agitation associated with bipolar disorders or schizophrenia.
  • The assessment indicates a potential addressable market of up to 86 million annual episodes of acute agitation in the at-home setting, with up to 1.8 million eligible patients.
  • Prescribers have expressed moderate to high interest in using IGALMI, with the potential to replace benzodiazepines that can cause dependence.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-02-06

Key Insights

  • BioXcel Therapeutics has entered into milestone and retention bonus agreements with key employees, including senior management, to incentivize them and ensure their retention as the company seeks FDA approval for its IGALMI drug for the acute treatment of agitation associated with bipolar disorders or schizophrenia.
  • The agreements provide for substantial cash bonuses, including an initial payment and a final payment in April 2026 subject to the employees remaining actively employed and the company not defaulting on its credit agreement.
  • The agreements also include provisions for accelerated payment of the final bonus amount if the company raises at least $25 million in capital or experiences a change of control or other material transaction prior to April 2026.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-01-20

Key Insights

  • BioXcel Therapeutics has submitted a supplemental New Drug Application (sNDA) to the FDA for the at-home use of its product IGALMI, which was previously approved for the acute treatment of agitation associated with schizophrenia or bipolar disorder under healthcare provider supervision.
  • If approved, the expanded label for IGALMI would provide a much-needed FDA-approved option for the at-home treatment of agitation in patients with bipolar disorders or schizophrenia.
  • The successful expansion of IGALMI's label could significantly increase the company's market opportunity and drive future revenue growth.
Sentiment: Positive Significance: 7/10
View Original Filing →
Current Report Filed: 2026-01-12

Key Insights

  • BioXcel Therapeutics, Inc. (BTAI) announced that Mark Pavao is joining the company as Interim Chief Commercial Officer to support the potential launch of IGALMI in the at-home setting.
  • The company plans to submit a supplemental New Drug Application (sNDA) this month seeking FDA approval of IGALMI for at-home use in the acute treatment of agitation associated with bipolar disorders or schizophrenia.
  • The company is transforming neuroscience through the strategic use of AI-driven drug discovery and human insight, reimagining existing medicines, and accelerating the development of innovative therapies to transform the standard of care in neuropsychiatry.
Sentiment: Positive Significance: 7/10
View Original Filing →
Insider Trading Filed: 2026-01-12

Key Insights

  • Sandeep Laumas, a director of BioXcel Therapeutics, Inc. (BTAI), has been granted a stock option to purchase 17,000 shares of the company's common stock.
  • The stock option has a strike price of $2.01 and will vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, subject to Laumas' continued service as a non-employee director.
  • This option grant suggests the company is compensating its directors to align their interests with those of shareholders and support the company's long-term growth.
Sentiment: Positive Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-01-12

Key Insights

  • Rajiv Patni, a director of BioXcel Therapeutics, Inc., has acquired 17,000 stock options with an exercise price of $2.01 and a 10-year expiration date.
  • The options will vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, subject to Patni's continued service as a non-employee director.
  • This insider transaction could signal Patni's confidence in the company's long-term prospects and alignment with shareholder interests.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-12

Key Insights

  • The reporting person, Peter Mueller, has been granted a stock option to acquire 17,000 shares of BioXcel Therapeutics, Inc. (BTAI) common stock, with an exercise price of $2.01 and a 10-year expiration date.
  • The stock option will vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, subject to the reporting person's continued service as a non-employee director.
  • This transaction represents an insider's acquisition of equity in the company, which could signal their confidence in the company's future performance.
Sentiment: Positive Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-01-12

Key Insights

  • Michal Votruba, a director of BioXcel Therapeutics, Inc. (BTAI), acquired 17,000 stock options on January 9, 2026 with an exercise price of $2.01 and a 10-year expiration date.
  • The options vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, subject to Votruba's continued service as a non-employee director.
  • Insider purchases, especially by directors, can signal confidence in the company's prospects and potential future stock price appreciation.
Sentiment: Positive Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-01-12

Key Insights

  • Michael Patrick Miller, a director of BioXcel Therapeutics, Inc. (BTAI), has been granted a stock option to purchase 17,000 shares of the company's common stock at an exercise price of $2.01 per share.
  • The option vests on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, subject to Miller's continued service as a non-employee director.
  • This transaction represents an insider purchase and could signal Miller's confidence in the company's future prospects.
Sentiment: Positive Significance: 5/10
View Original Filing →
Insider Trading Filed: 2026-01-12

Key Insights

  • Insider June Bray, a director at BioXcel Therapeutics, acquired 17,000 stock options with an exercise price of $2.01 and a 10-year term.
  • The stock options will vest on the earlier of the first anniversary of the grant date or the day before the next annual stockholder meeting, subject to Bray's continued service as a director.
  • This transaction suggests that an insider with knowledge of the company's operations believes the stock is undervalued and has confidence in the company's future performance.
Sentiment: Positive Significance: 6/10
View Original Filing →
Insider Trading Filed: 2026-01-12

Key Insights

  • The reporting person, David J. Mack, a director of BioXcel Therapeutics, Inc. (BTAI), acquired 17,000 stock options with an exercise price of $2.01 per share on January 9, 2026, which will vest on the earlier of the first anniversary of the grant date or the day before the next annual meeting of shareholders.
  • This insider transaction indicates Mack's continued commitment and confidence in the company's future prospects, as he has increased his direct ownership stake in BTAI.
  • The timing of the option grant, which occurs shortly before the next annual meeting, suggests it may be part of the company's director compensation program and aligns Mack's interests with those of other shareholders.
Sentiment: Positive Significance: 6/10
View Original Filing →

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.